Enjyoji K, Kato H, Hayashi I, Oh-ishi S, Iwanaga S
Department of Biology, Faculty of Science, Kyushu University, Fukuoka, Japan.
J Biol Chem. 1988 Jan 15;263(2):973-9.
Two T-kininogens (TI- and TII-kininogens) found in plasma of Freund's adjuvant-treated rats were purified by several chromatographic procedures. The isolated TI- and TII-kininogens showed different mobilities on polyacrylamide gel electrophoresis in the absence of sodium dodecyl sulfate, but were indistinguishable in the presence of sodium dodecyl sulfate. They were also indistinguishable in amino acid composition and antigenicity, but differed in sialic acid content. The NH2- and COOH-terminal sequences were determined. In the 30 NH2-terminal residues, 2 were different. The kinin regions in the COOH-terminal portions of the two kininogens have sequences that demonstrate TI-kininogen contains a mixture of two kinin-containing regions, with substitution of 4 amino acid residues, one of which is identical to the COOH-terminal portion of alpha 1-major acute phase protein (Cole, T., Inglis, A. S., Roxburgh, C. M., Howlett, G. J., and Schreiber, G. (1985) FEBS Lett. 182, 57-61) and the other to the COOH-terminal portion of TI-kininogen (Furuto-Kato, S., Matsumoto, A., Kitamura, N., and Nakanishi, S. (1985) J. Biol. Chem. 260, 12054-12059), both predicted from cDNA sequences. The amino acid sequence of the kinin-containing region from TII-kininogen is the same as the COOH-terminal portion of TII-kininogen predicted from the cDNA. These results indicate that T-kininogens from the plasma of adjuvant-treated rats consist of a family of kininogens, that is, TI- and TII-kininogens (separable on DEAE-Sephadex A-50), and that TI-kininogen consists of at least two variants (TI alpha and TI beta) which correspond to the alpha 1-major acute phase protein reported by Cole et al. and TI-kininogen reported by Furuto-Kato et al., respectively. Immunoblotting studies with plasmas from non-inflamed and adjuvant-treated rats also indicate that T-kininogen which was previously isolated from non-inflamed rat plasma corresponds to TI-kininogen and that TII-kininogen is newly generated after treatment of rats with adjuvants.
通过多种色谱方法对弗氏佐剂处理大鼠血浆中发现的两种T-激肽原(TI-和TII-激肽原)进行了纯化。在不存在十二烷基硫酸钠的情况下,分离得到的TI-和TII-激肽原在聚丙烯酰胺凝胶电泳上显示出不同的迁移率,但在存在十二烷基硫酸钠的情况下无法区分。它们在氨基酸组成和抗原性方面也无法区分,但唾液酸含量不同。测定了NH2-和COOH-末端序列。在30个NH2-末端残基中,有2个不同。两种激肽原COOH-末端部分的激肽区域具有的序列表明,TI-激肽原包含两个含激肽区域的混合物,有4个氨基酸残基被取代,其中一个与α1-主要急性期蛋白的COOH-末端部分相同(科尔,T.,英格利斯,A. S.,罗克斯堡,C. M.,豪利特,G. J.,和施赖伯,G.(1985年)《欧洲生物化学会联合会快报》182,57 - 61),另一个与TI-激肽原的COOH-末端部分相同(古留藤本,S.,松本,A.,北村,N.,和中西,S.(1985年)《生物化学杂志》260,12054 - 12059),两者均由cDNA序列预测得出。TII-激肽原含激肽区域的氨基酸序列与从cDNA预测的TII-激肽原的COOH-末端部分相同。这些结果表明,佐剂处理大鼠血浆中的T-激肽原由激肽原家族组成,即TI-和TII-激肽原(可在DEAE-葡聚糖A-50上分离),并且TI-激肽原至少由两种变体(TIα和TIβ)组成,它们分别对应于科尔等人报道的α1-主要急性期蛋白和古留藤本等人报道的TI-激肽原。对未发炎和佐剂处理大鼠血浆进行的免疫印迹研究还表明,先前从未发炎大鼠血浆中分离出的T-激肽原对应于TI-激肽原,并且TII-激肽原是在用佐剂处理大鼠后新产生的。